TABLE 1.

Pharmacokinetic parameters obtained with in vitro models

Drug	Regimen (mg/24 h)	Peak free concn (μg/ml) ± SD		Obtained half-life (h) ± SD
		Expected	Obtained
Gatifloxacin	100	0.84	0.71 ± 0.02	7.65 ± 0.3
	150	1.26	1.13 ± 0.01	8.16 ± 0.95
	175	1.47	1.22 ± 0.03	7.57 ± 0.62
	200	1.68	1.38 ± 0.01	8.65 ± 0.05
	400	3.36	2.79 ± 0.01	8.01 ± 0.18
Gemifloxacin	50	0.10	0.12 ± 0.03	7.45 ± 0.99
	75	0.15	0.17 ± 0.01	7.19 ± 0.22
	100	0.20	0.23 ± 0.01	8.22 ± 0.00
	150	0.30	0.31 ± 0.01	7.50 ± 0.01
	250	0.50	0.51 ± 0.02	7.22 ± 0.76
	320	0.64	0.62 ± 0.16	7.58 ± 0.88
Levofloxacin	500	4.13	4.10 ± 0.50	8.01 ± 0.69
	750	6.20	6.13 ± 0.10	7.52 ± 0.66
	812.5	6.71	6.78 ± 0.87	7.06 ± 0.26
	843.5	6.97	7.09 ± 0.55	6.98 ± 0.68
	875	7.23	7.19 ± 0.10	8.02 ± 0.02
	1000	8.26	8.75 ± 0.18	7.85 ± 0.90
Moxifloxacin	50	0.28	0.30 ± 0.01	12.33 ± 0.42
	75	0.42	0.45 ± 0.01	12.42 ± 0.46
	100	0.56	0.60 ± 0.00	12.02 ± 0.11
	200	1.13	1.10 ± 0.03	11.90 ± 0.42
	400	2.25	2.48 ± 0.15	11.66 ± 0.33
	800	4.50	4.46 ± 0.04	12.40 ± 0.96